IGF-1 DES
A truncated IGF-1 variant missing its first three amino acids, trading systemic reach for potent, short-lived anabolic action at the injection site.
IGF-1 DES is native human IGF-1 with the first three N-terminal amino acids (Gly-Pro-Glu) removed, leaving a 67-amino-acid peptide with sharply reduced affinity for IGF-binding proteins (IGFBPs) while retaining full IGF-1 receptor activation. Because it escapes IGFBP sequestration, more of the peptide is free and active locally, but its very short circulating half-life confines its effect largely to the site of injection. Occurring naturally in brain tissue and colostrum, it is sold only as a research-use-only compound and has no approved medical indication.
Class
Truncated IGF-1 analog (67-amino-acid peptide)
Half-life
~20-30 minutes in serum (minutes to a few hours)
Routes
Intramuscular (site-specific, preferred), Subcutaneous
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Higher local anabolic potency
By escaping IGFBP sequestration, IGF-1 DES leaves a larger free fraction available to bind IGF-1 receptors at the injection site, showing 2-10x greater potency than native IGF-1 in some cell-culture systems. Evidence is preclinical (cell culture and rodent).
Site-specific muscle hypertrophy
Its short systemic half-life means an intramuscular injection acts at and near the injected muscle rather than raising whole-body IGF-1, making it attractive for targeted hypertrophy in research-peptide bodybuilding protocols.
Activation of protein-synthesis signaling
Binding the IGF-1 receptor triggers the PI3K-Akt-mTOR and Ras-MAPK cascades that drive protein synthesis, cell growth, and inhibition of apoptosis.
Satellite cell activation
Preclinical work documents stimulation of satellite cell proliferation, a mechanism relevant to muscle repair and growth.
Lower systemic exposure than IGF-1 LR3
Rapid clearance minimizes sustained whole-body IGF-1 elevation, which lowers systemic side-effect and hypoglycemia risk relative to the long-acting LR3 analog at equivalent doses.
Mechanism
How it works
IGF-1 DES is native human IGF-1 with the first three N-terminal residues (Gly-Pro-Glu) removed. This truncation cuts the peptide's affinity for IGF-binding proteins roughly 10-fold. Since IGFBPs normally bind about 99% of circulating IGF-1 and regulate how much is bioavailable, stripping IGFBP affinity leaves nearly all administered DES free and able to reach IGF-1 receptors.
At the receptor, DES behaves like full-length IGF-1: it activates the IGF-1 receptor and the downstream PI3K-Akt-mTOR and Ras-MAPK signaling cascades that promote cell growth, protein synthesis, satellite cell proliferation, and suppression of apoptosis. The net effect is amplified local hypertrophic signaling without a proportional rise in systemic IGF activity.
The defining feature is pharmacokinetics. DES has a very short circulating half-life (roughly 20-30 minutes), so an injection produces a brief, high local concentration that acts at and near the injection site before rapid systemic clearance. This distinguishes it sharply from IGF-1 LR3, which is engineered for a long (20-30 hour) systemic half-life, and from native mecasermin, which is systemic but IGFBP-bound.
IGF-1 DES also occurs naturally in human brain tissue, cerebrospinal fluid, and colostrum. Its reduced IGFBP binding is proposed to give it greater bioavailability in CNS tissue, where IGFBP-2 normally limits IGF-1 activity, and it has been studied as an endogenous factor in neural development and neonatal gut maturation.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Reconstitute with bacteriostatic water. A 1 mg vial plus 1 mL BAC water yields 1000 mcg/mL, so 2 insulin-syringe units (0.02 mL) equals a 20 mcg starting dose. The peptide is fragile — inject within seconds of mixing. Store lyophilized at -20C; store reconstituted at 2-8C and use within 14 days.
Beginner
- Dose
- 20 mcg
- Frequency
- 3-4x per week
- Timing
- Post-workout, into the trained muscle
- Duration
- 4 weeks
- Route
- Intramuscular
Lowest starting dose; always eat within 30 minutes of injection to blunt hypoglycemia risk.
Intermediate
- Dose
- 40-60 mcg
- Frequency
- 4-5x per week
- Timing
- Post-workout
- Duration
- 4-6 weeks
- Route
- Intramuscular
Eat a carb-rich meal within 30 minutes of injection to manage hypoglycemia.
Advanced
- Dose
- 50-100 mcg
- Frequency
- Daily on training days
- Timing
- Post-workout, site-specific injection
- Duration
- Stay within 6-week cycles
- Route
- Intramuscular
Highest documented research-use range; keep cycles capped at 6 weeks.
- Typical documented dose range is 20-100 mcg, once daily on training days.
- Cycle structure is generally 4-6 weeks on followed by ~4 weeks off.
- Intramuscular injection into the trained muscle is preferred to exploit the peptide's local, site-specific action.
- Hypoglycemia is the most significant acute risk — always eat within 30 minutes of injecting.
- These are research-use figures compiled from community protocols; IGF-1 DES is not approved for human use and no clinical dosing exists.
Combinations
Stacking & blends
Post-Workout Local Growth Stack
Maximize site-specific hypertrophy and muscle repair
MGF (mechano growth factor) is commonly paired with IGF-1 DES post-workout to reinforce local satellite cell activation and repair at the trained muscle.
Anabolic + Tendon Support Stack
Muscle growth with connective-tissue and tendon support
BPC-157 is added for tendon and soft-tissue healing to complement the local anabolic action of IGF-1 DES.
GH-IGF Axis Stack
Combine downstream IGF-1 receptor activation with upstream GH release
CJC-1295 with Ipamorelin drives endogenous growth-hormone pulses while IGF-1 DES supplies direct local IGF-1 receptor activation, stacking the GH-IGF axis.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active malignancy or history of cancer
- Pregnancy and breastfeeding
- Hypoglycemia-prone individuals or use in a fasted state
- Active proliferative diabetic retinopathy
- Diabetes
- Cardiovascular conditions
Because of its short systemic half-life, sustained whole-body IGF-1 elevation and systemic side effects are less prominent than with IGF-1 LR3 or native IGF-1 at equivalent doses, and hypoglycemia risk is comparatively lower — but still real. Severe hypoglycemia can occur in a fasted state, and prolonged IGF-1 receptor activation carries a theoretical cancer-promotion concern based on epidemiology. Long-term human safety at research-use dosing is entirely uncharacterized, as no published human data exists.
FAQ
IGF-1 DES — common questions
How does IGF-1 DES differ from IGF-1 LR3?
IGF-1 DES has a short half-life and acts primarily locally at the injection site, whereas IGF-1 LR3 has a long half-life (20-30 hours) and produces systemic effects. Researchers use DES for site-specific anabolism and LR3 for sustained systemic IGF-1 receptor activation; they are not interchangeable, and stacking the two is discouraged because of overlapping mechanism and additive side-effect risk.
Why does IGF-1 DES cause hypoglycemia?
IGF-1 receptor activation produces insulin-like effects on glucose handling, which can drop blood sugar after injection. The risk is lower than with IGF-1 LR3 because of DES's much shorter systemic exposure, but it is significant enough that users are advised to eat within 30 minutes of every injection.
Is IGF-1 DES legal to purchase?
It is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption anywhere. It is sold strictly as a research-use-only compound.
Will IGF-1 DES ever be FDA-approved?
No active clinical development program exists, so approval is unlikely without a pharmaceutical sponsor renewing development. Only native IGF-1 (mecasermin, Increlex) is FDA-approved, for severe primary IGF-1 deficiency.
Does IGF-1 DES show up on a drug test?
Yes. IGF-1 and its analogs are on the WADA Prohibited List under Section S2 (Peptide Hormones), and anti-doping assays exist specifically to detect it.
How should IGF-1 DES be stored and handled?
Store the lyophilized powder at -20C and the reconstituted solution at 2-8C, using it within 14 days. The peptide is fragile, so it should be injected within seconds of mixing.
What evidence supports IGF-1 DES?
The evidence base is preclinical only — in vitro receptor-binding studies and rodent muscle models showing potent local anabolic effects, plus its role as an endogenous factor in brain tissue and colostrum. There are no published human clinical trials, pharmacokinetic studies, or controlled safety evaluations of administered IGF-1 DES.
